2017. Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s22. DOI:https://doi.org/10.25251/skin.1.supp.21.